**Table 14. Baseline (pre-CS) freezing levels for Figure 4.**

|  |
| --- |
| Figure 4 |
| Extinction Sessions |
| Group  | Baseline (% ± SEM) |
| No FootshockFootshock | 27.62 ± 14.331.9 ± 14.74 |
| Test |
| Group | Baseline (% ± SEM) |
| ControlFootshockNo Footshock | 49.44 ± 17.4851.9 ± 14.6910.95 ± 7 |
| Renewal |
| Group | Baseline (% ± SEM) |
| ControlFootshockNo Footshock | 68.33 ± 10.8156.67 ± 11.148.57 ± 13.68 |
| Spontaneous Recovery |
| Group | Baseline (% ± SEM) |
| ControlFootshockNo Footshock | 70.56 ± 5.1231.43 ± 15.1710.95 ± 6.62 |
| Reactivations |
| Group | Baseline (% ± SEM) |
| Day 3No Footshock + VehicleNo Footshock + NimodipineFootshock + VehicleFootshock + NimodipineDay 4No Footshock + VehicleNo Footshock + NimodipineFootshock + VehicleFootshock + NimodipineDay 5No Footshock + VehicleNo Footshock + NimodipineFootshock + VehicleFootshock + NimodipineDay 6No Footshock + VehicleNo Footshock + NimodipineFootshock + VehicleFootshock + Nimodipine | 60.95 ± 14.4768.57 ± 9.2244.29 ± 10.2555.71 ± 10.7747.62 ± 10.944.29 ± 11.9736.19 ± 9.0447.14 ± 14.3443.81 ± 8.6927.62 ± 7.4816.19 ± 7.9846.19 ± 13.7317.14 ± 10.0632.86 ± 12.7311.43 ± 8.2249.17 ± 14.44 |
| Test |
| Group | Baseline (% ± SEM) |
| No Footshock + VehicleNo Footshock + NimodipineFootshock + VehicleFootshock + Nimodipine | 29.05 ± 12.5521.91 ± 10.791.42 ± 1.14235 ± 12.18 |
| Renewal |
| Group | Baseline (% ± SEM) |
| No Footshock + VehicleNo Footshock + NimodipineFootshock + VehicleFootshock + Nimodipine | 42.86 ± 12.6310 ± 4.9317.14 ± 73640.83 ± 11.84 |
| Spontaneous Recovery |
| Group | Baseline (% ± SEM) |
| No Footshock + VehicleNo Footshock + NimodipineFootshock + VehicleFootshock + Nimodipine | 36.67 ± 9.5414.76 ± 8.6318.57 ± 7.9632 ± 9.48 |